The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway is crucial for the autocrine loop of type I interferons (IFNs) and is located upstream of important systemic lupus erythematosus (SLE)-associated pathogenic proinflammatory cytokines and chemokines. Baricitinib is a JAK 1/2 inhibitor approved for treating rheumatoid arthritis and is also being tested in other diseases, including SLE. Baricitinib improved the proportion of patients with SLE who achieved arthritis or rash resolution; however, the subset of patients with skin involvement was not reported in the study.1 Alopecia is one of the most common cutaneous symptoms in SLE. Patients can exhibit different subtypes of alopecia.2 Diffuse non-scarring hair loss, which is the most frequently observed type of alopecia in patients with SLE, is not life-threatening, but substantially affects quality of life for cosmetic reasons and may reflect latent …

中文翻译：

---

JAK 1/2抑制剂治疗系统性红斑狼疮所致弥漫性非瘢痕性脱发的疗效

Janus 激酶 (JAK)-信号转导和转录激活因子 (STAT) 通路对 I 型干扰素 (IFN) 的自分泌环至关重要，位于重要的系统性红斑狼疮 (SLE) 相关致病性促炎细胞因子和趋化因子的上游。Baricitinib 是一种 JAK 1/2 抑制剂，被批准用于治疗类风湿性关节炎，也在其他疾病中进行测试，包括 SLE。Baricitinib 改善了达到关节炎或皮疹消退的 SLE 患者的比例；然而，该研究并未报告皮肤受累患者的亚组。1 脱发是 SLE 中最常见的皮肤症状之一。患者可表现出不同的脱发亚型。 2 弥漫性非瘢痕性脱发，这是 SLE 患者最常观察到的脱发类型，不会危及生命，